ProfileGDS5678 / 1438559_x_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 95% 95% 95% 94% 95% 91% 93% 92% 93% 94% 94% 93% 93% 93% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 18.317895
GSM967853U87-EV human glioblastoma xenograft - Control 28.5208595
GSM967854U87-EV human glioblastoma xenograft - Control 38.4395995
GSM967855U87-EV human glioblastoma xenograft - Control 48.3430594
GSM967856U87-EV human glioblastoma xenograft - Control 58.364195
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 17.2162891
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 27.6873693
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 37.5400992
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.7634593
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 18.1862894
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 28.1119494
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.8454393
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.9929693
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.8598693